Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
 
ORIGINAL ARTICLE
Ahead of Print

Adjuvant radiotherapy for Stage I seminoma: A Single-institutional experience


1 Department of Radiation Oncology, Necmettin Erbakan University Meram Medicine School, Konya, Turkey
2 Department of Radiation Oncology, Ankara Numune Education and Research Hospital, Ankara, Turkey
3 Department of Radiation Oncology, Gazi University Faculty of Medicine, Ankara, Turkey
4 Department of Radiation Oncology, Kocaeli University Faculty of Medicine, Kocaeli, Turkey

Correspondence Address:
Gul Kanyilmaz,
Department of Radiation Oncology, Necmettin Erbakan University Meram Medicine School, Akyokus Mevkii, Konya
Turkey
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/jcrt.JCRT_916_16

Objectives: There is no consensus regarding the management of Stage 1 seminomas following inguinal orchiectomy. In this study, we evaluated the treatment results and treatment-related toxicity for patients with Stage 1 seminomas treated with adjuvant radiotherapy (RT) at a single institution. Methods: Sixty-five patients who underwent adjuvant RT following orchiectomy for Stage 1 seminomas between January 1996 and December 2007 were retrospectively reviewed. The age, tumor location, histopathological type, stage, tumor size, RT field, and radiation dose were recorded for all patients. Results: The patients' ages ranged from 17 to 61 years (median, 37 years). Sixty-three patients (97%) were diagnosed with classical seminoma and the remaining two patients (3%) had spermatocytic seminoma. After orchiectomy, 37 patients (57%) received para-aortic RT and 28 patients (43%) received dog-leg field RT. RT was applied with 1.8–2 Gy/day fractionation and the median RT dose was 26 Gy (range, 20–38). Follow-up ranged from 0.3 to 18 years (median, 9.5 years). Local control had been achieved in all patients and all of them were alive with no evidence of disease. Fifty-one patients (77%) had at least 5 years of follow-up and 27 patients (41%) had at least 10 years of follow-up. Overall survival at 10 years was 100%. Conclusion: Although retrospective in nature, this single-institutional study provides useful information about the outcomes and toxicities associated with adjuvant RT in patients with Stage 1 seminomas reporting excellent disease control and survival rates at the expense of acceptable toxicity.


Print this article
Search
 Back
 
  Search Pubmed for
 
    -  Kanyilmaz G
    -  Saricanbaz I
    -  Bora H
    -  Karahacioglu E
    -  Erkal EY
 Citation Manager
 Article Access Statistics
 Reader Comments
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed116    
    PDF Downloaded7    

Recommend this journal